Clinical Trials Browser

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT00310128 2016-02-03

Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

Phase 2 Withdrawn

Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, AIDS-Related, Lymphoma, Large-Cell, Anaplastic

NCT00227773 2015-10-08

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Phase 2 Withdrawn

Endocrine

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00072540 2013-11-08

S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix

Phase 2 Withdrawn

Gynecologic

Squamous Intraepithelial Lesions, Uterine Cervical Dysplasia

NCT00003455 2013-07-10

Antineoplaston Therapy in Treating Women With Advanced Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT00003486 2013-07-10

Antineoplaston Therapy in Treating Patients With Colon Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms

NCT00003502 2013-07-10

Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma

Phase 2 Withdrawn

Lymphoid

Lymphoma, Mantle-Cell

NCT00003517 2013-07-10

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

Phase 2 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT00112879 2013-07-10

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

Phase 2 Withdrawn

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00066417 2013-05-01

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

Phase 2 Terminated

51 enrolled

MyeloidOther hematologic neoplasm

Congenital Abnormalities, Blast Crisis, Leukemia, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00025051 2013-03-22

Celecoxib in Preventing Skin Cancer

Phase 2 Withdrawn

Dermatologic

Carcinoma, Basal Cell

NCT00265928 2008-01-28

Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 2 Terminated

46 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00294476 2006-10-12

IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma

Phase 2 Unknown

30 enrolled

DermatologicGastrointestinalGenitourinary

Colonic Neoplasms, Melanoma, Neoplasms, Urologic Neoplasms

Clinical Trials

Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission

Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix

Antineoplaston Therapy in Treating Women With Advanced Breast Cancer

Antineoplaston Therapy in Treating Patients With Colon Cancer

Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

Celecoxib in Preventing Skin Cancer

Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma